Please provide your email address to receive an email when new articles are posted on . Despite guidelines recommending early and aggressive therapy in RA, disease-modifying antirheumatic drug ...

Please provide your email address to receive an email when new articles are posted on . Maximizing the disease-modifying benefits of methotrexate is one of the core principles behind the 2021 American ...

rheumatoid arthritis dmard vs biologic Updated American College of Rheumatology recommendations suggest using first-line DMARDs in combination with biologic agents and nonbiologic DMARDs to achieve ...

A study looked at more than 23,600 Medicare beneficiaries with RA who had received a ≥30-day prescription of an opioid drug. Participants were grouped according to those who had been prescribed a ...

Etanercept can bind to and neutralize extracellular tumor necrosis factor, and has proven clinical efficacy in reducing the disease symptoms of patients with rheumatoid arthritis (RA) who cannot ...

Although low-dose glucocorticoids, in conjunction with DMARDs, are known to halt or severely retard the erosive destruction of joints in patients with early rheumatoid arthritis (RA), the potential ...

After the first 6 months of disease-modifying antirheumatic drugs (DMARDs) use in patients with rheumatoid arthritis (RA), most very abnormal results newly seen in long-term routine laboratory ...

Using a combination of three traditional disease-modifying antirheumatic drugs for treating recent-onset rheumatoid arthritis is not only more cost-effective, but results in better long-term worker ...

Researchers evaluated the risk for total hip and knee arthroplasty with regard to the use of NSAIDs, DMARDs, and TNF inhibitors in patients with psoriatic arthritis and ankylosing spondylitis.

Compared with cDMARDs, bDMARDs are associated with lower risks for cardiovascular events and all-cause mortality in psoriatic arthritis.

While overall risks for adverse birth outcomes were not increased in children born to fathers who used disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, for autoimmune diseases in ...